Make a ppt of 20 slides on topic first trimester pre eclampsia screening in detail from standard text books and recent guidelines
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Searching PubMed
preeclampsia first trimester screening combined test
Finding Sources
Searching PubMed
preeclampsia screening first trimester biomarkers
Searching the Web
first trimester preeclampsia screening FMF algorithm ACOG ISSHP 2024 guidelines
Finding Sources
Reading Article
Reading Web Page
first trimester preeclampsia screening algorithm MAP UtAPI PlGF aspirin
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Running Command
Writing File
Running Command
Running Command
Your presentation is ready. Download it here:
First Trimester PE Screening
Presentation · PPTX
What's Inside — 20 Slides
The deck uses a deep navy/teal/amber palette with a professional dark-panel design. Here is the complete slide outline:
| # | Slide Title | Key Content |
|---|---|---|
| 1 | Title Slide | Full title, subtitle, source attribution |
| 2 | Overview: What is Pre-Eclampsia? | ISSHP/ACOG definition, diagnostic criteria, classification, incidence |
| 3 | Epidemiology & Global Burden | 6 stat boxes — incidence, deaths, risk in twins, aspirin efficacy |
| 4 | Classification & Timing | Early/preterm/late-onset PE; severe features criteria; HELLP, eclampsia |
| 5 | Pathophysiology: Two-Stage Model | Stage 1 (placentation failure) vs. Stage 2 (maternal endothelial syndrome) |
| 6 | Angiogenic Imbalance | sFlt-1 vs. PlGF/PAPP-A — mechanisms, assay performance, sFlt-1/PlGF ratio |
| 7 | Risk Factors | High-risk (single factor sufficient) vs. moderate-risk factors in two-column layout |
| 8 | Why Screen in 1st Trimester? | Rationale, timing advantage, aspirin window, superiority over risk-factor-only |
| 9 | FMF Combined Algorithm — Components | Four pillars: maternal factors, MAP, UtA-PI, PlGF (+PAPP-A) |
| 10 | MAP Measurement | Protocol, clinical significance, angiotensin II sensitivity data |
| 11 | Uterine Artery PI (UtA-PI) | Technique, interpretation, standalone vs. combined performance |
| 12 | PlGF and PAPP-A | Biochemistry, assay thresholds, two-stage strategy |
| 13 | Performance Statistics Table | Full comparison table — 7 screening strategies × 3 PE types, colour-coded |
| 14 | FMF Bayes Model & Risk Calculation | Algorithm mechanics, MoM conversion, 1:100 threshold, validation data |
| 15 | Guideline Comparison | FMF/FIGO vs. NICE vs. ACOG/USPSTF vs. ISSHP/SMFM |
| 16 | Screening Protocol (Step-by-Step) | 5-step clinical workflow from CRL to risk counselling |
| 17 | Aspirin Prophylaxis | ASPRE trial, 62% reduction, 150 mg nocte, dosing, safety, timing |
| 18 | Additional Prevention / What Doesn't Work | Calcium, statins, metformin vs. vitamins C&E, sodium restriction, bed rest |
| 19 | Special Populations & Monitoring | Twins, chronic HTN, diabetes, APS; post-screen surveillance protocol |
| 20 | Key Takeaways | 7 numbered evidence-based conclusions with full references |
Primary sources used: Creasy & Resnik's Maternal-Fetal Medicine 8e (Ch. 45), FIGO 2020 initiative, ASPRE Trial (Rolnik et al., NEJM 2017), Lee et al. Best Pract Res Clin Obstet Gynaecol 2024, ACOG Practice Bulletin 222, ISSHP 2021, USPSTF 2023.
This is a shared conversation. Sign in to Orris to start your own chat.